Articles By Jack Cush, MD
Modest Efficacy for Methotrexate in Psoriasis
Doubt remains regarding the appropriateness, efficacy and safety of methotrexate in the treatment of moderate to severe cutaneous psoriasis. Moreover, high dose, subcutaneous MTX has not been studied in a well-designed trial.
Read Article
The RheumNow Week in Review – 3 February 2017
Dr. Jack Cush reviews this week's highlights from RheumNow.
Read Article
Kevzara (Sarilumab) Approved in Canada for RA
Kevzara (sarilumab), an interleukin-6 (IL-6) receptor monoclonal antibody, was approved by Health Canada for use in rheumatoid arthritis (RA).
Read Article
Gout is Undermanaged
Gout should be one of the easiest and best managed of rheumatic disorders. However, numerous deficits exist with regard to the treatment and long-term care of gout.
Read Article
Limited Efficacy of NSAIDs in Spondyloarthritis
Prior to the biologic era, nonsteroidal antiinflammatory drugs (NSAIDs) were the mainstay of drug therapy in thos with spondyloarthritis (SpA) and ankylosing spondylitis (AS). Their role in the modern era has changed and the claims for efficacy have varied.
Read Article
Is the Jury Still Out on Triple Therapy vs. MTX + TNF inhibitor?
There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis.
Read Article
Curbside Consults - January 2017
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.
Read Article
The RheumNow Week in Review – 27 January 2017
Dr. Cush reviews highlights from the past week on RheumNow.com.
Read Article
The Challenge of Screening for Obstructive Sleep Apnea
A JAMA article presents the US Public Health Task Force review of OSA testing.
Read Article
DSB - Safety Update and Drug Shortages January 2017
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Read Article
